Drug
Dordaviprone clinical trials
Also written ONC201 and TIC10.
- studies test it
- 25
- open now
- 6
- in phase 3
- 2
- first study started
- 2014
Keep track of what changes. Save the dordaviprone studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Studies by the year they started
25 studies that test it; most in 2015 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 13
- Phase 2
- 15
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 18
Chimerix (5) · University of Nebraska (2) · National Cancer Institute (NCI) (2) · Fox Chase Cancer Center (2) · Rutgers, The State University of New Jersey (2) · Jazz Pharmaceuticals (2) · M.D. Anderson Cancer Center (2) · Peter Anderson (1)
Often tested with
Tested in the same studies.
GDC-0084 (1) · Tasadenoturev (1) · Paclitaxel (1) · Atezolizumab (1) · Ixazomib (1) · Dexamethasone (1)
Studies
Open first, then newest update. How each study uses dordaviprone is read from its arms, and is right about nine times in ten.
Testing it · 25
- Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0RecruitingPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT05476939Written as ONC201
- Testing for Safety and Colorectal Cancer Preventive Effects of ONC201RecruitingPhase 1National Cancer Institute (NCI)NCT05630794Written as Dordaviprone Hydrochloride
- Combination Therapy for the Treatment of Diffuse Midline GliomasRecruitingPhase 2University of California, San FranciscoNCT05009992Written as ONC201
- ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian CancerRecruitingPhase 2Ira WinerNCT04055649Written as Akt/ERK Inhibitor ONC201
- ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)RecruitingPhase 3Jazz PharmaceuticalsNCT05580562Written as Dordaviprone (ONC201)
- ONC201 and Atezolizumab in Obesity-Driven Endometrial CancerRecruitingPhase 1UNC Lineberger Comprehensive Cancer CenterNCT05542407Written as ONC201
- Single Agent ONC201 in Recurrent or Metastatic Endometrial CancerTerminatedPhase 2Fox Chase Cancer CenterNCT03099499Written as ONC201
- ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic SyndromeTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT02392572Written as Akt/ERK Inhibitor ONC201
- ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell TransplantCompletedPhase 1University of NebraskaNCT03932643Written as ONC-201
- A Study of ONC201 for Refractory MeningiomaWithdrawnPhase 2University of NebraskaNCT06012929Written as ONC201
- ONC201 in Adults With Recurrent H3 K27M-mutant GliomaTerminatedPhase 2Jazz PharmaceuticalsNCT03295396Written as Dordaviprone (ONC201)
- ONC201 in Pediatric H3 K27M GliomasTerminatedPhase 1ChimerixNCT03416530Written as Dordaviprone (ONC201)
- ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial CancerTerminatedPhase 2ChimerixNCT03485729Written as Dordaviprone (ONC201)
- Oral ONC201 in Adult Recurrent GlioblastomaTerminatedPhase 2ChimerixNCT02525692Written as Dordaviprone (ONC201)
- Phase 2 Study of ONC201 in Neuroendocrine TumorsCompletedPhase 2Peter AndersonNCT03034200Written as ONC201
- Oral ONC201 in Relapsed/Refractory Multiple MyelomaTerminatedPhase 1/2ChimerixNCT02863991Written as ONC201
- A Phase II, Open Label Study of ONC201 in Adults With EGFR-low GlioblastomaWithdrawnPhase 2Masonic Cancer Center, University of MinnesotaNCT04629209Written as ONC201
- ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial CarcinomaCompletedPhase 2National Cancer Institute (NCI)NCT03394027Written as ONC201
- Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT02420795Written as Akt/ERK Inhibitor ONC201
- A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple MyelomaCompletedPhase 1Fox Chase Cancer CenterNCT02609230Written as ONC-201
See all 25 studies that test dordaviprone →
Given in every arm · 1 — dordaviprone is usual care beside what is tested
Codes
What other systems call dordaviprone · ClinicalTrials.gg INT006410
- MeSH (NLM) C585684dordaviproneConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 9U35A31JAIDORDAVIPRONEConfirmed FDA, NLM, Wikidata
- Wikidata Q27895916DordaviproneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C113792DordaviproneOne source FDA
- DrugBank DB14844One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C585684 | dordaviprone | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 9U35A31JAI | DORDAVIPRONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27895916 | Dordaviprone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C113792 | Dordaviprone | One source FDA |
| DrugBank | DB14844 | — | One source Wikidata |
Also registered as dordaviprone hydrochloride (UNII 53VG71J90J).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.